"We are excited about these trial results, which show that 1.0 mg semaglutide injected once weekly provided better glycaemic control and greater weight loss than 2.0 mg exenatideonce-weekly," chief science officer Mads Krogsgaard Thomsen said in a statement. Novo Nordisk said semaglutide appeared to have a safe and well-tolerated profile.
Novo Nordisk successfully completes diabetes drug phase 3a trial
Friday, 25 September 2015
Novo Nordisk successfully completes diabetes drug phase 3a trial
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment